Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 86, Issue 3, Pages 515-524Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2021.09.075
Keywords
binimetinib; cobimetinib; cutaneous melanoma; dabrafenib; encorafenib; imiquimod; interleukin-2; ipilimumab; laherparepvec; nivolumab; pembrolizumab; talimogene; trametinib; vemurafenib
Categories
Ask authors/readers for more resources
This article provides dermatologists with an up-to-date working knowledge of the treatment options prescribed by oncologists for patients with unresectable stage III, stage IV, and recurrent melanoma, who often cannot undergo surgical clearance due to the nature of their disease.
Despite advances in early detection as described in part 1 of this continuing medical education series, melanoma continues to be a large contributor to cutaneous cancer-related mortality. In a subset of patients with unresectable or metastatic disease, surgical clearance is often not possible; therefore, systemic and local therapies are considered. The second article in this series provides dermatologists with an up-to-date working knowledge of the treatment options that may be prescribed by oncologists for patients with unresectable stage III, stage IV, and recurrent melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available